Trial Profile

A pilot trial will assess the bioequivalence of ondansetron administered as a orally dissolving thin film strip [Zuplenz; MonoSol Rx, Strativa Pharmaceuticals] and as an orally dissolving tablet [Zofran; GlaxoSmithKline] for the prevention of nausea and vomiting induced by moderate or highly emetogenic chemotherapy or radiotherapy.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 29 Jan 2018

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ondansetron (Primary)
Indications Chemotherapy-induced nausea and vomiting; Nausea and vomiting; Radiotherapy-induced nausea and vomiting
Focus Pharmacokinetics
Sponsors MonoSol Rx; Par Specialty Pharmaceuticals

30 Nov 2017 According to a Aquestive Therapeutics media release, MonoSol Rx changed its name to Aquestive Therapeutics
02 Dec 2008 New source identified and integrated (media release from Strativa)
25 Feb 2008 New trial record.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com